Katkin Keith's Form 4 filing
Syndax Pharmaceuticals Inc (SNDX) · filed Oct 7, 2022
- Accession no.
- 0001562180-22-007125
- Filed
- Oct 7, 2022
- Trade date
- Oct 6, 2022
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $774.4K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Katkin KeithCIK 0001314596 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 6, 2022 | Common Stock | MOption exerciseAcquired | +20,782 | $7.88 | +$163,762.16 | 52,782 | Direct | |
| Oct 6, 2022 | Common Stock | SSaleDisposed | −20,782 | $25.90 | −$538,253.8 | 32,000 | Direct | |
| Oct 6, 2022 | Common Stock | MOption exerciseAcquired | +9,117 | $8.93 | +$81,414.81 | 41,117 | Direct | |
| Oct 6, 2022 | Common Stock | SSaleDisposed | −9,117 | $25.90 | −$236,130.3 | 32,000 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 6, 2022 | Common Stock | MOption exerciseDisposed | −9,117 | $0.00 | $0 | 0 | Direct | |
| Oct 6, 2022 | Common Stock | MOption exerciseDisposed | −20,782 | $0.00 | $0 | 0 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.